Condition: Esophageal Cancer · Adenocarcinoma of the Esophagus · Sponsor: Erasmus Medical Center
Both neoadjuvant chemoradiotherapy (CROSS) and neoadjuvant chemotherapy (FLOT) have demonstrated overall survival benefit over surgery alone in esophageal and esophagogastric junction (EGJ) cancer. Despite these survival gains, the prognosis remains poor, especially in patients with nodal-positive adenocarcinoma (cN+ AC) (5-year survival 36%, compared to 55% for cN0). This highlights the need for more effective treatment options, and justifies treatment intensification in these patients. The aim of this study is to determine the efficacy and feasibility of TNT FLOT-CROSS and TNT CROSS-FLOT in patients with resectable, cN+ AC of the esophagus or EGJ.
This description comes directly from the study's public registry record.
Bianca Mostert, MD, PhD · +31107041906 · b.mostert@erasmusmc.nl
Esmee A de Bruijn, MD · 0031107034523 · e.debruijn@erasmusmc.nl
Always discuss trial participation with your own doctor first.
| Catharina Ziekenhuis | Eindhoven, North Brabant, Netherlands | Not Yet Recruiting |
| Frisius medisch centrum | Leeuwarden, North Brabant, Netherlands | Not Yet Recruiting |
| Elisabeth Tweesteden Ziekenhuis | Tilburg, North Brabant, Netherlands | Not Yet Recruiting |
| Amsterdam UMC | Amsterdam, North Holland, Netherlands | Not Yet Recruiting |
| Erasmus Medical Centre | Rotterdam, South Holland, Netherlands | Recruiting |
| Ziekenhuisgroep Twente | Almelo, Netherlands | Not Yet Recruiting |
| Antoni van Leeuwenhoek/Nederlands Kanker Instituut | Amsterdam, Netherlands | Not Yet Recruiting |
| Gelre ziekenhuis | Apeldoorn, Netherlands | Not Yet Recruiting |
| Leids Universitair Medisch Centrum | Leiden, Netherlands | Not Yet Recruiting |
| Radboud Universitair Medisch Centrum | Nijmegen, Netherlands | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06161818